Skip to main content

Security report for amicusrx.com

Amicus Therapeutics · Healthcare · United States

Low risk. 2 critical or high findings in Security headers and SSL/TLS.

Security score

83/100

Risk levelLow

0–100, higher is better. How it is calculated

Amicus Therapeutics is a well-established global biotechnology company specializing in the discovery, development, and delivery of therapies for rare metabolic diseases. The company targets patients, healthcare professionals, and investors with a comprehensive digital presence that includes detailed information on their pipeline, patient advocacy programs, and investor relations. Their market position is that of a specialized rare disease biotech firm with a strong global footprint, evidenced by multiple country-specific domains and localized content. Technically, the website is built on WordPress and leverages modern web technologies including jQuery, Google Analytics, Google Tag Manager, and various social media tracking pixels. The site demonstrates good mobile optimization, SEO practices, and a professional design, although performance is moderate rather than fast. The hosting provider is GoDaddy, and the domain is long-standing and consistent with the company's founding date. From a security perspective, the site uses HTTPS and implements cookie consent via OneTrust, indicating compliance with privacy regulations such as GDPR. However, there is room for improvement in security posture, including enabling DNSSEC, adding security headers like Content-Security-Policy, and publishing a security policy or vulnerability disclosure. No critical vulnerabilities or malicious content were detected. Overall, the website presents a trustworthy and professional image with strong business credibility and privacy compliance. The main risks relate to security best practices and transparency around incident response and vulnerability management. Strategic improvements in these areas would enhance the company's digital trust and security maturity.

Scanned

NIS2 and GDPR posture

GDPR outside view
88/ 100 · Low
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

2 findings rated critical or high. Fix these first.

  1. Security headers

    Security headers are instructions your web server sends to every visitor’s browser. Missing ones leave visitors more exposed to attacks such as clickjacking and injected scripts.

    • High

      Missing Content-Security-Policy header

      Controls resources the browser is allowed to load

      What to do: Implement a Content-Security-Policy appropriate for your application

      • ASVS V3.4.3
      • OWASP Secure Headers: OWASP Secure Headers Project recommends Content-Security-Policy: default-src 'self'; form-action 'self'; base-uri 'self'; object-src 'none';…

  2. SSL/TLS

    TLS encrypts the connection and proves the site is really yours. Weak or expiring certificates trigger browser warnings and put traffic at risk.

    • High

      Weak Protocols Supported

      Server supports weak protocols: TLSv1.1

      What to do: Disable TLS 1.0, TLS 1.1, and all SSL versions

      • CWE-327
      • OWASP A04:2025
      • ASVS V12.1.1

Need hands-on remediation? Email guard@offseq.com

Keep watching amicusrx.com

This scan found 15 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. The full timeline opens with your unlock code.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
62
Security headers
80
Email security
80
DNS health
90
Network security
100
GDPR outside view
88
Average
83

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

Amicus Therapeutics operates in the healthcare biotechnology sector with a focus on rare metabolic diseases. Their business model centers on pharmaceutical development and patient-centric advocacy, supported by clinical trials and expanded access programs. The company maintains a global presence with localized domains for multiple countries, indicating a broad market reach. Investor relations are prominently featured, suggesting a publicly traded or investor-focused entity. The company leverages digital marketing and analytics tools to engage stakeholders and optimize outreach. Growth indicators include active pipeline programs and patient advocacy initiatives. Partnerships appear to be primarily internal subsidiaries or country-specific branches rather than external third-party collaborations.

Security posture

The website demonstrates a moderate security maturity level with HTTPS enforced and cookie consent mechanisms in place. However, the absence of DNSSEC, security.txt, and explicit security policies indicates gaps in comprehensive security governance. The lack of advanced security headers and incident response contact information may expose the organization to risks related to web-based attacks or delayed incident handling. No exposed sensitive data or vulnerable libraries were detected in the provided content. Compliance with GDPR is supported by cookie consent and privacy policy presence. Overall, the security posture is adequate but could benefit from enhancements in DNS security, header policies, and transparency around security operations.

Recommendations

  1. Enable DNSSEC on the domain to protect against DNS spoofing and improve domain security.
  2. Publish a security policy and incident response contact information on the website to enhance transparency and readiness.
  3. Implement additional security headers such as Content-Security-Policy and X-Content-Type-Options to mitigate common web vulnerabilities.
  4. Create and publish a vulnerability disclosure policy or security.txt file to encourage responsible reporting of security issues.
  5. Regularly audit and update third-party scripts and libraries to ensure no vulnerabilities are introduced.
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
Amicus Therapeutics
Description
Amicus Therapeutics is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering high-quality medicines for people living with rare metabolic diseases.
Key services
drug development, patient advocacy programs, expanded access programs, clinical trials
Content quality
good
Branding
consistent

Technology

Stack
jQuery, Google Analytics, Google Tag Manager, Mouseflow, LinkedIn Insight Tag, Twitter Universal Website Tag, Facebook Pixel, OneTrust Cookie Consent
Frameworks
WordPress
Platforms
Web
Performance
moderate
Mobile
good
Accessibility
basic
SEO
good

Security

Observed score
70/100
Good practices seen
  • HTTPS enforced
  • Use of security related scripts (Google Tag Manager, Facebook Pixel etc.)
  • Cookie consent mechanism implemented

Analytics and tracking

Services
Google Analytics, Mouseflow
Tracking level
moderate
Privacy practices
good

Advertising

Tracking pixels
Facebook Pixel, Twitter Universal Website Tag, LinkedIn Insight Tag
Marketing tools
Mouseflow
Transparency
good

Site quality

Design
good
User experience
good
Content relevance
good
Navigation
good
Professionalism
good
Trustworthiness
high

Key observations

  1. Website is professionally designed and well-structured.
  2. Content is focused on rare disease biotechnology and patient advocacy.
  3. Multiple country-specific domains indicate global presence.
  4. Cookie consent and privacy compliance mechanisms are implemented.
  5. No visible security policy or incident response information.
  6. No security.txt or vulnerability disclosure found.
  7. No suspicious or malicious content detected.
  8. Social media presence is active and linked.
  9. WHOIS data supports legitimacy and long-term operation.
Technical notes

Notes

The website is built on WordPress CMS with a modern front-end leveraging jQuery and various analytics and marketing scripts including Google Analytics, Google Tag Manager, Facebook Pixel, Twitter Tag, LinkedIn Insight, and Mouseflow. The site uses OneTrust for cookie consent management, indicating attention to privacy compliance. Hosting is provided by GoDaddy, with domain registration dating back to 2007, consistent with the company's history. Performance is moderate, with some heavy media content such as background videos on the homepage. Mobile optimization is good, and SEO metadata is well implemented with Open Graph and JSON-LD structured data. Accessibility features are basic but present. There is no evidence of outdated or vulnerable libraries in the provided content.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Earlier scans of this domain

  1. 56/100Medium21 findingsView report
Reviews of this site

Share your experience with amicusrx.com. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review amicusrx.com.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.